Akademik Veri Yönetim Sistemi
HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI, cilt.60, sa.3, ss.270-275, 2022 (ESCI)
Aim: Psoriasis is thought to result in vascular diseases, atherogenesis, peripheral insulin resistance, and cardiac comorbidities by causing metabolic function disorders, hypertension, and type 2 diabetes. To our best knowledge, there has not yet been a study evaluating psoriasis patients with regard to copeptin. The present study assesses cardiovascular disease in psoriasis patients based on metabolic function and copeptin levels. Methods: The presented case-control study, which is a type of analytical observational study, included 45 psoriasis patients and an age-sex matched control group admitted to University of Health Sciences Turkey, Istanbul Haseki Training and Research Hospital, Clinic of Dermatology, between March 2016 and May 2017. Patients' blood pressure, height, weight, body mass index, and waistline were measured for both groups. All subjects were also given complete blood count, fasting blood glucose (FBG), uric acid, lipid profile, insulin, C-reactive protein (CRP), copeptin levels, neutrophil-lymphocyte rate, and thrombocyte-lymphocyte rate were analysed. Copeptin was measured by an ELISA kit. Results: Insulin and CRP averages were statistically significantly higher in psoriasis patients than in the control group (p=0.001 for both). The neutrophil-lymphocyte and thrombocyte-lymphocyte rates were significantly higher in psoriasis patients (p=0.008). Insulin resistance was also higher in psoriasis patients (p=0.001). In both the patient and control groups, there was no statistically significant relationship found between copeptin level, general characteristics, and laboratory parameters. Conclusion: To our best knowledge, this is the first study evaluating psoriasis patients with regard to copeptin. Psoriasis patients should be followed up with easily accessible parameters such as neutrophil-lymphocyte rate, thrombocyte-lymphocyte rate, insulin levels, FBG, and uric acid levels.